statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BOSTON, MA / ACCESSWIRE / March 27, 2024 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) provided a corporate update today announcing a strategy to maximize its ability to capture the potential...

Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potential

StockNews.com assumed coverage on shares of Pieris Pharmaceuticals (NASDAQ:PIRS  Free Report) in a report published on Wednesday. The firm issued a hold rating on the biotechnology...

Pieris Pharmaceuticals (NASDAQ:PIRS) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Pieris Pharmaceuticals (NASDAQ:PIRS  Free Report) in a report published on Tuesday morning. The firm issued a hold rating on the biotechnology...

Pieris Pharmaceuticals (NASDAQ:PIRS) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of Pieris Pharmaceuticals (NASDAQ:PIRS  Free Report) in a research note issued to investors on Tuesday morning. The brokerage issued a hold rating on...

Pieris Pharmaceuticals (NASDAQ:PIRS) Receives New Coverage from Analysts at StockNews.com

StockNews.com began coverage on shares of Pieris Pharmaceuticals (NASDAQ:PIRS  Free Report) in a research note issued to investors on Wednesday. The firm issued a hold rating on the...

StockNews.com Begins Coverage on Pieris Pharmaceuticals (NASDAQ:PIRS)

Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. Its pipeline includes immuno-oncology, respiratory, and anemia and other disease areas. The company was founded by Claus Schalper and Arne Skerra in 2001 and is headquartered in Boston, MA.

Volume	40,170.00
52-Wk High	$80.80
52-Wk Low	$10.89

PIRS Pieris Pharmaceuticals Inc

About

Feed

News

Sentiment

Earnings

Fundamentals